Immuto Scientific is an AI-enabled therapeutics company discovering disease-specific targets defined by changes in protein structure on the cell surface and developing advanced antibody-based medicines against them. Its structural surfaceomics platform measures these conformational changes across cell-surface proteins in living, disease-relevant systems, generating proprietary data that conventional genomics, expression-based approaches, and standard surface mapping can’t capture. Immuto uses AI to prioritize targets, build conformational models informed by empirical data and available structural models, and optimize antibodies for affinity and developability. Using this approach, Immuto is advancing a proprietary pipeline of antibody therapeutics alongside partnered programs with pharmaceutical companies, with an initial focus in oncology.

‍